Longevity Foundation
91
상호작용
3
12,000
intermediate
May 17, 2026
개요
The Longevity Foundation stack addresses three fundamental pillars of biological aging: telomere attrition, extracellular matrix degradation, and immune senescence. Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It activates telomerase — the enzyme that rebuilds telomere caps on chromosomes — in somatic cells. In Khavinson''s clinical studies, Epithalon administration to elderly patients was associated with reduced mortality, improved immune markers, and normalization of melatonin production from the pineal gland. It is administered in 10-day cycles, typically twice per year. GHK-Cu is a naturally occurring copper-binding tripeptide that functions as a master regulator of tissue remodeling. Beyond its surface-level skin benefits, GHK-Cu modulates the expression of over 4,000 genes — many involved in DNA repair, antioxidant production (SOD, glutathione), stem cell proliferation, and suppression of pro-inflammatory cytokines. Its concentration in human plasma drops from 200 ng/mL at age 20 to 80 ng/mL by age 60, correlating with visible aging and reduced regenerative capacity. Thymosin Alpha-1 addresses immunosenescence — the progressive decline of immune function with age that increases susceptibility to infections, cancer, and autoimmune conditions. By promoting T-cell maturation, dendritic cell activation, and natural killer cell function, Ta1 helps restore immune surveillance to more youthful levels. The three-peptide combination creates a comprehensive anti-aging protocol: Epithalon maintains chromosomal integrity, GHK-Cu restores tissue remodeling capacity and gene expression patterns, and Thymosin Alpha-1 rejuvenates immune competence. This represents a systems-biology approach to aging rather than targeting any single pathway.
용량 프로토콜
10,000 mcg
1회 용량당
500 mcg
1회 용량당
1,500 mcg
1회 용량당
목표 및 증거
경고
- Epithalon and GHK-Cu were removed from the FDA Category 2 list (April 2026) but remain pending PCAC review — not legal to compound yet. Thymosin Alpha-1 remains FDA Category 2 (restricted) in the US (approved abroad as Zadaxin). Epithalon cycles: 10 days on, 6 months off.
Comments
Sign in to join the discussion
주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.